SK pharmteco to invest $200 million in US pharmaceutical capacity

SK pharmteco has announced a five-year investment plan exceeding $200 million to expand and modernize its development and production infrastructure in the United States. The initiative focuses on increasing capacities for small molecule active pharmaceutical ingredients (APIs) and peptides.

The investment aims to strengthen the company's supply chain resilience and meet growing demand from a diverse customer base. Key components of the plan include the establishment of new development laboratories, additional peptide purification capabilities, and modernized GMP-compliant production lines. These upgrades are expected to be phased in starting in 2026, integrating the entire value chain from laboratory workflows to scalable manufacturing.